bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Should You Sell?

by · The Markets Daily

bioMerieux (OTCMKTS:BMXMF – Get Free Report) shares gapped down prior to trading on Friday. The stock had previously closed at $88.6650, but opened at $84.06. bioMerieux shares last traded at $85.00, with a volume of 2,000 shares trading hands.

Analyst Upgrades and Downgrades

BMXMF has been the topic of a number of research analyst reports. Morgan Stanley restated an “underweight” rating on shares of bioMerieux in a research note on Friday, September 11th. Zacks Research raised shares of bioMerieux from a “strong sell” rating to a “hold” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, Piper Sandler initiated coverage on shares of bioMerieux in a research note on Thursday, June 11th. They set a “neutral” rating for the company. Five investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, bioMerieux currently has an average rating of “Reduce”.

Check Out Our Latest Analysis on BMXMF

bioMerieux Stock Performance

The stock has a 50 day moving average price of $83.27 and a two-hundred day moving average price of $87.43.

About bioMerieux

(Get Free Report)

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.

Further Reading